Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: This multicenter retrospective study evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with donafenib and a programmed death-1 (PD-1) inhibitor (TACE+DP) and TACE combined with donafenib (TACE+D) for unresectable hepatocellular carcinoma (uHCC).
Methods: The clinical data of 388 patients with uHCC who received TACE+DP or TACE+D as first-line treatment at six Chinese academic centers from July 2021 to July 2022 were collected and analyzed retrospectively. Patients in the TACE+DP group received an intravenous administration of a PD-1 inhibitor every three weeks and oral donafenib (0.2 g) twice daily until intolerable toxicity or disease progression. Patients in the TACE+D group received the same dose of donafenib for 3-5 days after TACE. Overall survival (OS) and progression-free survival (PFS)were analyzed by Kaplan-Meier method and log-rank test. The tumor response was compared between the two groups according to modified RECIST criteria. Adverse events were also analyzed between the two groups.
Results: The TACE+D group included 157 patients and the TACE+DP group included 166 patients. Patients in the TACE+DP group had a longer median OS (18.1 vs. 13.2 months, P<0.001) and longer median PFS (10.6 vs. 7.9 months, P<0.001) than those in the TACE+D group. Patients in the TACE+DP group achieved a greater objective response rate (ORR; 50.6% vs. 41.4%, P=0.019) and greater disease control rate (DCR) (89.2% vs. 82.8%, P=0.010) than those in the TACE+D group. No significant differences were found in the incidence or severity of adverse events between the TACE+DP and TACE+D groups (any grade: 92.9% vs. 94.6%, P=0.270; grade 3 or 4: 33.8% vs. 37.3%, P=0.253).
Conclusion: With favorable safety and tolerability, TACE combined with donafenib and PD-1 inhibitors significantly improved PFS, OS, and ORR compared to TACE combined with donafenib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711098 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1277329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China.
J Hepatocell Carcinoma
August 2025
Department of Hepatobiliary and Pancreatic Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.
Background: Unresectable hepatocellular carcinoma (uHCC) remains a major clinical challenge with limited effective therapeutic options. Triple therapy combining interventional treatments, donafenib, and anti-PD-1 monoclonal antibodies has shown promise in recent studies, but real-world data remain limited.
Objective: To evaluate the real-world efficacy and safety of triple therapy with interventional treatment, donafenib, and anti-PD-1 monoclonal antibodies in patients with uHCC.
Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib.
Front Cell Dev Biol
August 2025
Laboratory of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. It is often diagnosed at advanced stages, which limits treatment options. Although Donafenib is a standard therapy for advanced HCC, its effectiveness is often reduced by treatment failures.
View Article and Find Full Text PDFDonafenib lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.
Quant Imaging Med Surg
August 2025
Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: The combination of tyrosine kinase inhibitors (TKIs) with transarterial chemoembolization (TACE) holds promise for unresectable hepatocellular carcinoma (HCC). This study aimed to directly compare the efficacy and safety of donafenib (Dona)-TACE lenvatinib (LEN)-TACE as first-line therapies.
Methods: In this retrospective study, 93 unresectable HCC patients (49 Dona-TACE, 44 LEN-TACE; 93% hepatitis B virus-infected) treated between October 2020 and May 2023 were analyzed.
Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study.
J Hepatocell Carcinoma
July 2025
Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Purpose: To evaluate the efficacy and safety of hepatic artery infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin (FOLFOX-HAIC) combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma (uHCC).
Patients And Methods: This retrospective study analyzed clinical data from 49 uHCC patients treated with FOLFOX-HAIC, donafenib tablets, and camrelizumab at the First Affiliated Hospital of Chongqing Medical University between November 1, 2021, and November 30, 2024. The primary endpoint was the objective response rate (ORR), assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.
Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma.
World J Gastrointest Oncol
June 2025
Department of Laboratory Medicine, Nantong First People's Hospital and The Second Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China.
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide and currently lacks effective treatment options. This is particularly true for advanced HCC, for which conventional therapies often lead to a poor prognosis.
Aim: To assess the safety and efficacy of transarterial chemoembolization (TACE) with donafenib and immune checkpoint inhibitors (ICIs) for unresectable HCC.